| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
CEO | President And CEO
1 company
Crockett Thomas Andrew is a CEO at KalVista Pharmaceuticals, Inc.. Recent SEC Form 4 filings include 0 buys and 11 sells.
Estimated insider holdings value: $5.7M based on current market prices.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Feb 20, 2024 | KALV Kalvista Pharmaceuticals, Inc. | CEO | Sale+OE | 24,888 | $14.11 | $351,289.14 | -10.5% | -13.9% | -22.4% | |
| Feb 14, 2024 | KALV Kalvista Pharmaceuticals, Inc. | CEO | Sell | 58,356 | $15.01 | $875,882.71 | -24.3% | -13.3% | -33.8% | |
| Feb 1, 2024 | KALV Kalvista Pharmaceuticals, Inc. | CEO | Sell | 10,000 | $16.22 | $162,198.44 | -4.1% | -22.6% | -43.4% | |
| Dec 27, 2023 | KALV Kalvista Pharmaceuticals, Inc. | CEO | Sell | 30,000 | $12.02 | $360,453.00 | -19.0% | -7.7% | -26.7% | |
| Nov 20, 2023 | KALV Kalvista Pharmaceuticals, Inc. | CEO | Sale+OE | 14,807 | $8.23 | $121,851.25 | -8.6% | +68.1% | +10.2% | |
| Aug 18, 2023 | KALV Kalvista Pharmaceuticals, Inc. | CEO | Sale+OE | 14,876 | $10.73 | $159,601.63 | -9.2% | -29.4% | +11.3% | |
| May 18, 2023 | KALV Kalvista Pharmaceuticals, Inc. | CEO | Sale+OE | 5,627 | $10.14 | $57,082.54 | -4.2% | +3.7% | +14.6% | |
| Feb 17, 2023 | KALV Kalvista Pharmaceuticals, Inc. | CEO | Sale+OE | 6,700 | $7.66 | $51,322.00 | -5.2% | +28.1% | +83.0% | |
| Nov 18, 2022 | KALV Kalvista Pharmaceuticals, Inc. | CEO | Sale+OE | 1,785 | $5.44 | $9,710.40 | -1.5% | +49.7% | +59.5% | |
| Sep 2, 2022 | KALV Kalvista Pharmaceuticals, Inc. | CEO | Sell | 1,320 | $17.01 | $22,457.69 | -1.2% | -66.9% | -34.0% |